Get access

A new paradigm in cell therapy for diabetes: Turning pancreatic α-cells into β-cells

Authors

  • Caroline B. Sangan,

    1. Centre for Regenerative Medicine, Department of Biology & Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
    Search for more papers by this author
  • David Tosh

    Corresponding author
    1. Centre for Regenerative Medicine, Department of Biology & Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
    • Centre for Regenerative Medicine, Department of Biology & Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
    Search for more papers by this author

Abstract

Cell therapy means treating diseases with the body's own cells. One of the cell types most in demand for therapeutic purposes is the pancreatic β-cell. This is because diabetes is one of the major healthcare problems in the world. Diabetes can be treated by islet transplantation but the major limitation is the shortage of organ donors. To overcome the shortfall in donors, alternative sources of pancreatic β-cells must be found. Potential sources include embryonic or adult stem cells or, from existing β-cells. There is now a startling new addition to this list of therapies: the pancreatic α-cell. Thorel and colleagues recently showed that under circumstances of extreme pancreatic β-cell loss, α-cells may serve to replenish the insulin-producing compartment. This conversion of α-cells to β-cells represents an example of transdifferentiation. Understanding the molecular basis for transdifferentiation may help to enhance the generation of β-cells for the treatment of diabetes.

Get access to the full text of this article

Ancillary